CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Sugammadex vs Neostigminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03579589
NCT03579589Phase 1Completed
CompareCT.gov

The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal in Outpatient Surgeries - An Evaluation of Clinical and Associated Health Care Cost

Ohio State University·interventional·Posted Jul 6, 2018·Updated Aug 11, 2021

In Brief

A Phase 1 clinical trial evaluating Sugammadex vs Neostigmine for Neuromuscular Blockade. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Patients who undergo surgery receive drugs called neuromuscular blocking agents (NMBA) that to block the activity of muscles. When the surgery is over, the block needs to be reversed. Suggammadex and neostigmine are examples of drugs that reverse blocks. This study aims to investigate if sugammadex is associated with a significantly reduced time to discharge from the operating room to the postoperative unit when compared to neostigmine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuromuscular Blockade
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJul 6, 2018
Enrollment StartAug 15, 2018
Primary CompletionDec 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.0 years ago

Interventions

Sugammadex vs Neostigminedrug

Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.